New approach to remove toxic agent that causes myotonic dystrophy
Cell biologists from the Radboud University Nijmegen Medical Centre (Nijmegen, the Netherlands) describe a new approach to remove the toxic agent that causes the neuromuscular disease myotonic...
View ArticleLoss of key proteins may account for molecular abnormalities associated with...
Research on the genetic defect that causes myotonic muscular dystrophy has revealed that the mutation disrupts an array of metabolic pathways in muscle cells through its effects on two key proteins.
View ArticleMedication used to treat heart arrhythmias also reduces myotonic dystrophy:...
A medication most often used to treat heart arrhythmias also reduces a central symptom of myotonic dystrophy, the most common type of muscular dystrophy in adults.
View ArticleInvasive strategy benefits patients with myotonic dystrophy type 1...
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing...
View ArticleMyotonia less important to patients with myotonic dystrophy than other symptoms
Complex, multi-system diseases like myotonic dystrophy - the most common adult form of muscular dystrophy - require physicians and patients to identify which symptoms impact quality of life and,...
View ArticleResearchers hold new implications for pathogenesis of myotonic dystrophy
An important breakthrough could help in the fight against myotonic dystrophy. The discovery, recently published in the prestigious scientific journal Cell, results from an international collaboration...
View ArticleMexiletine use improves stiffness in patients with nondystrophic myotonias
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the...
View ArticleMexiletine improves patient-reported stiffness in nondystrophic myotonia
An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and...
View ArticleHeart drug could ease rare muscle disorder
The anti-arrhythmic drug mexiletine may improve symptoms in patients with nondystrophic myotonias, shows a small randomized trial published in JAMA.
View ArticleSystemic delivery of antisense oligonucleotides neutralizes mutant RNA...
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling...
View ArticleIsis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients
Isis Pharmaceuticals, Inc. announced today that it has initiated a study for ISIS-DMPK Rx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the...
View ArticleMedication used to treat heart arrhythmias also reduces myotonic dystrophy:...
A medication most often used to treat heart arrhythmias also reduces a central symptom of myotonic dystrophy, the most common type of muscular dystrophy in adults.
View ArticleInvasive strategy benefits patients with myotonic dystrophy type 1...
Patients with a cardiac irregularity and myotonic dystrophy type 1 (a severe neuromuscular disorder with a high risk of sudden death) who received an invasive treatment strategy that included testing...
View ArticleMyotonia less important to patients with myotonic dystrophy than other symptoms
Complex, multi-system diseases like myotonic dystrophy - the most common adult form of muscular dystrophy - require physicians and patients to identify which symptoms impact quality of life and,...
View ArticleResearchers hold new implications for pathogenesis of myotonic dystrophy
An important breakthrough could help in the fight against myotonic dystrophy. The discovery, recently published in the prestigious scientific journal Cell, results from an international collaboration...
View ArticleMexiletine use improves stiffness in patients with nondystrophic myotonias
Preliminary research finds that for patients with nondystrophic myotonias (NDMs), rare diseases that affect the skeletal muscle and cause functionally limiting stiffness and pain, use of the...
View ArticleMexiletine improves patient-reported stiffness in nondystrophic myotonia
An older medication originally approved to treat heart problems eases the symptoms of a very rare muscle disease that often leaves its sufferers stiff and in a good deal of pain, physicians and...
View ArticleHeart drug could ease rare muscle disorder
The anti-arrhythmic drug mexiletine may improve symptoms in patients with nondystrophic myotonias, shows a small randomized trial published in JAMA.
View ArticleSystemic delivery of antisense oligonucleotides neutralizes mutant RNA...
By targeting the specific mutation that causes the hereditary neuromuscular disease myotonic dystrophy, it is possible to neutralize the mutant RNA toxicity and minimize or even eliminate the disabling...
View ArticleIsis Pharmaceuticals begins ISIS-DMPK Rx clinical study in DM1 patients
Isis Pharmaceuticals, Inc. announced today that it has initiated a study for ISIS-DMPK Rx in patients with Myotonic Dystrophy Type 1 (DM1). DM1 is a rare genetic neuromuscular disease caused by the...
View Article